Biodel, Inc. (Nasdaq:BIOD) reported new information regarding the mechanism of action of VIAject (injectable prandial insulin) and an update on previously reported findings regarding the effects of VIAject on microvascular function in patients with type 2 diabetes. VIAject is an investigational ultra-rapid-acting injectable human insulin which Biodel is developing as a treatment for diabetes.
In a poster presentation at the American Diabetes Association 69th Scientific Sessions, Dr. Roderike Pohl and colleagues from Biodel described results of in vitro studies to explain VIAject’s mechanism of absorption and rapid onset of action (poster #438, Rapidity of Hexameric Dissociation of Various Prandial Insulin Formulations). VIAject was shown to have a smaller mean particle size compared to rapid acting insulin analogs and regular human insulin. These data are consistent with an increased proportion of monomeric/dimeric insulin after injection into the subcutaneous space, a key contributor to VIAject’s more rapid absorption that has been previously demonstrated in clinical studies.
In a separate presentation, Dr. Thomas Forst and colleagues from the Institute for Clinical Research and Development (ikfe), Mainz, Germany, described results of a clinical study comparing the effect of VIAject to regular human insulin and insulin lispro on markers of oxidative stress and endothelial function following a liquid test meal in patients with type 2 diabetes (poster #1304, Postprandial Vascular Effects of VIAject Compared with Insulin Lispro and Regular Human Insulin in Patients with Type 2 Diabetes Mellitus). VIAject was found to be the most effective of the three insulins in reducing post-prandial oxidative stress and improving microvascular blood flow and function. These findings were presented previously at the Eighth Annual Diabetes Technology Meeting in November 2008.
No Comment Received
Leave A Reply